These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 8471415)

  • 21. Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (nirvanol) in humans.
    Küpfer A; Patwardhan R; Ward S; Schenker S; Preisig R; Branch RA
    J Pharmacol Exp Ther; 1984 Jul; 230(1):28-33. PubMed ID: 6747829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.
    Brøsen K; Skjelbo E; Flachs H
    Br J Clin Pharmacol; 1993 Aug; 36(2):105-8. PubMed ID: 8398577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. S-mephenytoin hydroxylation phenotypes in a Jordanian population.
    Hadidi HF; Irshaid YM; Woosley RL; Idle JR; Flockhart DA
    Clin Pharmacol Ther; 1995 Nov; 58(5):542-7. PubMed ID: 7586948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous high-performance liquid chromatography-electrochemical detection determination of imipramine, desipramine, their 2-hydroxylated metabolites, and imipramine N-oxide in human plasma and urine: preliminary application to oxidation pharmacogenetics.
    Koyama E; Kikuchi Y; Echizen H; Chiba K; Ishizaki T
    Ther Drug Monit; 1993 Jun; 15(3):224-35. PubMed ID: 8333003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects.
    Schellens JH; van der Wart JH; Breimer DD
    Br J Clin Pharmacol; 1990 Jun; 29(6):665-71. PubMed ID: 2378787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design.
    Schellens JH; van der Wart JH; Brugman M; Breimer DD
    J Pharmacol Exp Ther; 1989 May; 249(2):638-45. PubMed ID: 2724144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine.
    Brøsen K; Zeugin T; Meyer UA
    Clin Pharmacol Ther; 1991 Jun; 49(6):609-17. PubMed ID: 2060250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenotypic differences in mephenytoin pharmacokinetics in normal subjects.
    Wedlund PJ; Aslanian WS; Jacqz E; McAllister CB; Branch RA; Wilkinson GR
    J Pharmacol Exp Ther; 1985 Sep; 234(3):662-9. PubMed ID: 4032286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population.
    Basci NE; Brosen K; Bozkurt A; Isimer A; Sayal A; Kayaalp SO
    Br J Clin Pharmacol; 1994 Nov; 38(5):463-5. PubMed ID: 7893589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Active metabolites of imipramine and desipramine in man.
    Potter WZ; Calil HM; Sutfin TA; Zavadil AP; Jusko WJ; Rapoport J; Goodwin FK
    Clin Pharmacol Ther; 1982 Mar; 31(3):393-401. PubMed ID: 7060321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sparteine and mephenytoin oxidation: genetic polymorphisms in east and west Greenland.
    Clasen K; Madsen L; Brøsen K; Albøge K; Misfeldt S; Gram LF
    Clin Pharmacol Ther; 1991 Jun; 49(6):624-31. PubMed ID: 2060251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A major pathway of mephenytoin metabolism in man. Aromatic hydroxylation to p-hydroxymephenytoin.
    Küpfer A; Brilis GM; Watson JT; Harris TM
    Drug Metab Dispos; 1980; 8(1):1-4. PubMed ID: 6102023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients.
    Spina E; Pollicino AM; Avenoso A; Campo GM; Caputi AP
    Int J Clin Pharmacol Res; 1993; 13(3):167-71. PubMed ID: 8225700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative mapping of metabolites of imipramine and desipramine in plasma samples by gas chromatographic-mass spectrometry.
    Narasimhachari N; Saady J; Friedel RO
    Biol Psychiatry; 1981 Oct; 16(10):937-44. PubMed ID: 7306616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study.
    Ward SA; Helsby NA; Skjelbo E; Brøsen K; Gram LF; Breckenridge AM
    Br J Clin Pharmacol; 1991 Jun; 31(6):689-92. PubMed ID: 1867963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians.
    Inaba T; Jurima M; Nakano M; Kalow W
    Clin Pharmacol Ther; 1984 Nov; 36(5):670-6. PubMed ID: 6488688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro microsomal metabolism of imipramine under conditions mimicking the in vivo steady-state situation.
    Linnet K
    Hum Psychopharmacol; 2004 Jan; 19(1):31-6. PubMed ID: 14716709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers.
    Koyama E; Chiba K; Tani M; Ishizaki T
    J Pharmacol Exp Ther; 1996 Jul; 278(1):21-30. PubMed ID: 8764331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Genetic polymorphism of oxidative drug metabolism. Therapeutic and toxicologic implications].
    Eichelbaum M
    Internist (Berl); 1983 Mar; 24(3):117-27. PubMed ID: 6135670
    [No Abstract]   [Full Text] [Related]  

  • 40. Urinary desipramine hydroxylation index and steady-state plasma concentrations of imipramine and desipramine.
    Spina E; Arena A; Pisani F
    Ther Drug Monit; 1987 Jun; 9(2):129-33. PubMed ID: 3617150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.